Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancer

Choe, Eun Kyung; Yi, Jin Wook; Chai, Young Jun; Park, Kyu Joo

doi:10.1002/jso.25078

Cited by 42 publications

(30 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sakellariou [13] and Gialamas [6] found that AdipoR1 is negatively associated with nodal stage and AdipoR2 is positively associated with TNM and shorter survival in lower stages of disease. In 2018, Chloe et al showed that increased tissue AdipoR1 messenger ribonucleic acid (mRNA) is associated with increased mortality and shorter OS [14]. Conversely, Ayyildiz et al [12] showed that tissue AdipoR1 and AdipoR2 have no influence on survival.…”

Section: Adiponectin (Apn)mentioning

confidence: 99%

The prognostic and therapeutic role of hormones in colorectal cancer: a review

et al. 2018

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the commonest cancers in Western society with a poor prognosis in patients with advanced disease. Targeted therapy is of increasing interest and already, targeted hormone treatment for breast and prostate cancer has improved survival. The aim of this literature review is to summarise the role of hormones in CRC prognosis and treatment. A literature review of all human and animal in vivo and in vitro studies in the last 20 years, which assessed the role of hormones in CRC treatment or prognosis, was carried out. The hormones described in this review have been subdivided according to their secretion origin. Most of the studies are based on in vitro or animal models. The main findings point to adipokines, insulin and the insulin growth factor axis as key players in the link between obesity, type 2 diabetes mellitus and a subset of CRC. Gut-derived hormones, especially uroguanylin and guanylin are being increasingly investigated as therapeutic targets, with promising results. Using hormones as prognostic and therapeutic markers in CRC is still in the preliminary stages for only a fraction of the hormones affecting the GIT. In light of the increasing interest in tailoring treatment strategies, hormones are an important area of focus in the future of CRC management.

show abstract

Section: Adiponectin (Apn)mentioning

confidence: 99%

The prognostic and therapeutic role of hormones in colorectal cancer: a review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Similarly, SPP1 could not only promote CRC cell growth and migration, but it also inhibited autophagy, which may be thus achieved by activating the p38MAPK signaling pathway [29]. In addition, a study by Choe et al [30] also confirmed higher SPP1 expression along with shorter survival times in CRC patients.…”

Section: Discussionmentioning

confidence: 89%

Identification and verification of 3 key genes associated with survival and prognosis of patients with colon adenocarcinoma via integrated bioinformatics analysis

Liu¹,

Li²,

Dong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is the third most lethal malignancy in the world, wherein colon adenocarcinoma (COAD) is the most prevalent type of CRC.Exploring biomarkers is important for the diagnosis, treatment, and prevention of COAD. Methods: We used GEO2R and Venn online software for differential gene screening analysis. Hub genes were screened via STRING and Cytoscape, following Gene Ontology and KEGG enrichment analysis. Finally, survival analysis and expression validation were performed via UALCAN online software, real-time PCR and immunohistochemistry. Results: In this study, we screened 323 common differentially expressed genes from four GSE datasets. Furthermore, four hub genes were selected for survival correlation analysis and expression level verification, three of which were shown to be statistically significant. Conclusion: Our study suggests that SERPINE1, SPP1 and TIMP1 may be biomarkers closely related to the prognosis of CRC patients.

show abstract

“…Although prior studies have not addressed the association between the ADIPOR expression and prognosis in ovarian cancer, its upregulation was associated with poor survival in colorectal cancer. 41 The correlation between ADIPOR expression and tumor aggressiveness has also been demonstrated in esophageal and breast cancer. 42,43 Further studies are needed to clarify the predictive value of the ADIPOR in EOC and to identify therapeutic target against APN.…”

Section: Discussionmentioning

confidence: 96%

CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer

et al. 2019

View full text Add to dashboard Cite

Objectives: Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. The oncogenic role of adiponectin is not known with regard to various cancer types. We sought to determine the role of adiponectin in angiogenesis in ovarian cancer in vitro. Methods: We transfected SKOV3 cells with vascular endothelial growth factor small interfering RNA in order to identify the independent angiogenic role of adiponectin in ovarian cancer. The vascular endothelial growth factor knockdown SKOV3 cell lines were treated with adiponectin for 48 h. The cytokines involved in adiponectin-mediated angiogenesis were explored using the human angiogenesis cytokine array and were verified with the enzyme-linked immunosorbent assay. The angiogenic effect of adiponectin was evaluated using the human umbilical vein endothelial cell tube formation assay. We also investigated the effects of adiponectin treatment on the migration and invasion of SKOV3 cells. Results: The number of tubes formed by human umbilical vein endothelial cell decreased significantly after knockdown of vascular endothelial growth factor (via transfection of vascular endothelial growth factor small interfering RNA into SKOV3 cells). When these vascular endothelial growth factor knockdown SKOV3 cells were treated with adiponectin, there was an increase in the number of tubes in a tube formation assay. Following adiponectin treatment, the CXC chemokine ligand 1 secretion increased in a cytokine array. This was confirmed by both enzyme-linked immunosorbent assay and Western blot. The increased secretion of CXC chemokine ligand 1 by adiponectin occurred regardless of vascular endothelial growth factor knockdown. In addition, the induction of migration and invasion of SKOV3 cells were significantly stronger with adiponectin treatment than they were without. Conclusion: Adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor. These findings suggest that adiponectin may serve as a novel therapeutic target for ovarian cancer.

show abstract

Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancer

Abstract: Upregulation of ADIPOR1 and SPP1, among the adipokine gene family, in cancer tissue is associated with poor survival in CRC, suggesting a potential mechanism linking obesity and CRC. ADIPOR1 and SPP1 expression could become useful prognostic indicators after further validation.

Cited by 42 publications

References 45 publications

The prognostic and therapeutic role of hormones in colorectal cancer: a review

The prognostic and therapeutic role of hormones in colorectal cancer: a review

Identification and verification of 3 key genes associated with survival and prognosis of patients with colon adenocarcinoma via integrated bioinformatics analysis

CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer

Contact Info

Product

Resources

About